NKTR Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe substantial cash balance and projected runway provide funding for pivotal trials and operations through key 2028 readouts. This reduces near-term financing pressure and gives management greater flexibility to advance rezpeg without relying immediately on additional capital.
Late-stage Pipeline ProgressProgress into registrational development materially advances the company toward potential product approval and commercialization. FDA alignment and active Phase 3 execution strengthen the pipeline’s strategic position, although meaningful value realization still depends on future trial results.
Durable Clinical DifferentiationDurable responses and the potential for less frequent maintenance dosing could differentiate rezpeg from existing therapies and improve its future treatment convenience. If confirmed in Phase 3, these attributes may support physician adoption and strengthen the commercial profile in large immune dermatology markets.
Bears Say
Persistent Losses And Cash BurnThe company continues to consume substantial cash while generating very large operating and net losses. This weak earnings base makes financial performance dependent on available funding and eventual clinical success, limiting resilience if development costs rise or programs take longer than planned.
Limited Recurring RevenueNear-term revenue remains modest and is not supported by a broad commercial product portfolio, leaving collaboration and royalty receipts as the main source of income. Until rezpeg or another asset reaches approval, the business lacks a recurring product-revenue base to offset development spending.
Long, Uncertain Development TimelineThe lead programs require several years of execution before potential regulatory submissions, leaving substantial exposure to trial outcomes, competitive developments, and regulatory interactions. Delays or unfavorable data could extend losses and postpone any transition from development-stage economics to product commercialization.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is CHF1.05B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Aug 13, 2026. The company reported -CHF1.015 earnings per share for the quarter, beating the consensus estimate of -CHF1.626 by CHF0.611.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -1.71.
How many shares outstanding does Nektar Therapeutics have?
Currently, no data Available
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -CHF1.015 in its last earnings report, beating expectations of -CHF1.626. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in CH:NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF109.29 (― Upside)
CHF109.29 (― Upside)
Blogger Sentiment
Bullish
CH:NKTR Sentiment 71%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth CHF35.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.51%
12-Months-Change
Fundamentals
Return on Equity
-37.99%
Trailing 12-Months
Asset Growth
427.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple substantial positive developments: initiation of the global Phase 3 program in atopic dermatitis, FDA-aligned registrational design for alopecia areata, strong Phase 2b signals (efficacy, durability, favorable safety), robust cash balance after a $350M offering, and encouraging market research supporting commercial potential. Offsetting these positives are expected higher R&D and G&A spend, a meaningful quarterly net loss, modest near-term revenue largely from non-cash royalties, a cash runway that covers key mid-2028 readouts but leaves limited buffer for delays, and an ongoing litigation matter. On balance the strategic, clinical, and financial highlights outweigh the risks described on the call.View all CH:NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
―Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―